Phase I CAR T-cell therapy for relapsed or refractory acute lymphoblastic leukemia in children, adolescents, and young adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase I trial uses an academic manufacturing approach to deliver two different CAR T-cell products matched to disease biomarkers in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia. Patients with CD19+/- CD22+ B-ALL receive autologous CD19/CD22 CAR T cells, while patients with T-ALL receive allogeneic CAR T cells using an NKG2D receptor. The primary goals are to determine feasibility and safety, with close monitoring for toxicity, CAR T-cell persistence, and early signs of remission. Patients who enter remission may proceed to allogeneic hematopoietic stem cell transplant per investigator judgment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ARM A: CD19+/- CD22+ B-ALL with relapsed or refractory disease not responding to conventional chemotherapy and with no other curative therapy available. Treatment with previous CART CD19 therapy is permitted, but is not mandatory, OR:
* ARM B: T-ALL with relapsed or refractory disease not responding to conventional chemotherapy and with no other curative therapy available.
* Patients diagnosed with ALL must be suitable for allogeneic HSCT and willing to proceed to transplant if the CART treatment induces complete remission and the investigator believes it is the best option.
* For ARM B there must be a suitable haploidentical donor (following local standard operating procedures).
* Lansky (age \<16 years) or Karnofsky (age ≥16 years) score of 50 or greater.
* Life expectancy greater than 12 weeks.
* Absolute neutrophil count (ANC) ≥ 500/μL unless, in the opinion of the investigator, cytopenia is due to underlying leukemia and is potentially reversible with leukemia therapy.
* Platelet count ≥ 50,000/μL unless, in the opinion of the investigator, cytopenia is due to underlying leukemia and is potentially reversible with leukemia therapy.
* Absolute lymphocyte count ≥ 100/μL.
* Adequate renal, hepatic, pulmonary, and cardiac function.
* Adequate venous access and absence of contraindications for lymphoapheresis
* Patients with a seizure disorder may be enrolled if well controlled with anticonvulsants.
* Patients or patients' legal representative, parent(s), or guardian able to provide written informed consent.

Exclusion Criteria:

* Enrolled in another clinical trial in the previous 4 weeks.
* Active infection requiring systemic medical therapy including clinically significant viral infection or uncontrolled viral reactivation of EBV, CMV, adenovirus, BK-virus, HHV-6 or Aspergillus.
* Any of the following cardiac criteria: cardiac echocardiography with LVSF\<30% or LVEF\<40%; or clinically significant pericardial effusion.
* Presence of CNS-3 disease or uncontrolled seizure disorder.
* Active immunosuppressive therapy with the exception of prednisone 10 mg/day (or equivalent), within 7 days prior to enrolment.
* GFR \<30 ml/min or bilirubin \>3 times the upper limit of normality (unless due to Gilbert's syndrome).
* Any other condition that, in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the trial.
* Pregnant or lactating women.
* Sexually active patients must be willing to utilize one of the more effective birth control methods for at least 12 months after the infusion and until CAR-T cells are no longer present on two consecutive tests. Male partner should use a condom. Women of child-bearing potential are defined as all women physiologically capable of becoming pregnant.
* Sexually active males should use a condom during intercourse for at least 12 months after the infusion and until CAR-T cells are no longer present on two consecutive tests.

Where it's running

• Hospital Universitario La Paz
  Madrid, Madrid, Spain Recruiting

Study contacts

• Study coordinator: Antonio Pérez Martínez, MD
• Email: aperezmartinez@salud.madrid.org
• Phone: 917 27 75 76

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Isometric wall squat exercise to lower blood pressure in adults with hypertension

  We’re testing whether doing isometric wall squats at home for 12 weeks can help lower 24-hour blood pressure in adults with essential hypertension.

  Recruiting Korea University Guro Hospital · Seoul, Seoul · NCT07868822

• Ring-style blood pressure bracelet test compared with 24-hour monitoring in people with HFrEF

  A ring-type blood pressure device is being tested to see if its 24-hour readings match those from standard ambulatory monitoring in adults with heart failure and reduced ejection fraction.

  Recruiting Keimyung University Dongsan Medical Center · Daegu · NCT07626879

• TSLPR-CART therapy for CRLF2-R/TSLPR–expressing B-ALL in adults

  This study tests a CAR T-cell treatment called TSLPR-CART in adults whose B-ALL cells overexpress TSLPR and have not responded to standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07572136

• Virtual buddy movement program to improve motor and social skills in children in remission from leukemia

  This 12-week program will test whether virtual buddy-led movement therapy helps children aged 5–12 in remission from precursor cell lymphoblastic leukemia improve motor skills and social interaction.

  Recruiting Comenius University · Bratislava · NCT07522905

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

• CART BP Pro-guided management for people with uncontrolled high blood pressure

  This project will see if using the wearable CART BP Pro ring to guide treatment helps lower blood pressure more than usual office-based care for adults in Korea whose blood pressure is not controlled.

  Recruiting at 3 sites Korea University Anam Hospital · Ansan and 2 other locations · NCT07465549

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.